Latin America Bladder Cancer Therapeutics & Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 3.40 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Latin America Bladder Cancer Therapeutics & Diagnostics Market Analysis
Based on the data from the International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. As per the data from the World Health Organization (2018), the number of new cases of Bladder cancer in Brazil was 9,127 which is around 3.3% of the total cancers that occurred in 2018.
In recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developing regions such as Latin America. Also, the rise of different therapies such as immunotherapy in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management.
Hence, the increasing awareness about bladder cancer and related therapies, the Latin America bladder cancer therapeutics and diagnostics market is expected to grow in the coming future. Apart from this, factors like increasing healthcare expenditure and innovations in novel drug development are also contributing to the growth of this market.
Latin America Bladder Cancer Therapeutics & Diagnostics Market Trends
This section covers the major market trends shaping the Latin America Bladder Cancer Therapeutics & Diagnostics Market according to our research experts:
Radiation Therapy is Expected to Cover a Large Share of the Market
Bladder cancer is highly prevalent and increases with age. As per a 2016 report by Cancer Research UK, the incidence of bladder cancer increases with age. Moreover, the geriatric population in Latin America countries is expected to increase in the future as per a 2017 report by the United Nations titled "World Population Ageing" 2017. This factor is expected to increase the number of bladder cancer patients in future.
The most advanced modalities of bladder cancer therapeutics include immunotherapy but, the most widely used modality in bladder cancer is radiation therapy. This is due to historical use-prevalence of radiation therapies in various forms of cancers and also because chemotherapy is associated with low specificity and side-effects. Radiation therapy also, offers best in class efficacy, in terms of dose frequency and pricing, when compared to other therapeutic modalities in bladder cancer management. Advancements in radiation therapy and expected increase in number of bladder cancer patients is expected to help the growth of this market.
Latin America Bladder Cancer Therapeutics & Diagnostics Industry Overview
The Latin America bladder cancer market is moderately competitive and majorly dominated by the global players. With the rising technology and focus of various companies on the drug discovery, it has been believed that several new companies will be entering the market in the coming future and are expected to hold a significant market share.
Latin America Bladder Cancer Therapeutics & Diagnostics Market Leaders
-
Pfizer Inc
-
Johnson and Johnson
-
AstraZeneca Plc.
-
Bristol Myers Squibb
-
Merck & Co Inc
*Disclaimer: Major Players sorted in no particular order
Latin America Bladder Cancer Therapeutics & Diagnostics Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies
-
4.2.2 Increasing Healthcare Expenditure
-
4.2.3 Innovations in Drug Development
-
-
4.3 Market Restraints
-
4.3.1 Rise in the number of Patent Expirations
-
4.3.2 Asymptomatic Nature of the Disease
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Cancer Type
-
5.1.1 Transitional Cell Bladder Cancer
-
5.1.2 Superficial Bladder Cancer
-
5.1.3 Invasive Bladder Cancer
-
5.1.4 Squamous Cell Bladder Cancer
-
5.1.5 Other Rare Types
-
-
5.2 By Therapeutics and Diagnostics
-
5.2.1 By Therapeutics
-
5.2.1.1 Chemotherapy
-
5.2.1.2 Immunotherapy
-
5.2.1.3 Radiation Therapy
-
5.2.1.4 Surgery
-
-
5.2.2 By Diagnostics
-
5.2.2.1 Cytoscopy
-
5.2.2.2 Biopsy
-
5.2.2.3 Urinalysis
-
5.2.2.4 Urine Ctyology
-
5.2.2.5 Bladder Ultrasound
-
-
-
5.3 Geography
-
5.3.1 Latin America (LATAM)
-
5.3.1.1 Mexico
-
5.3.1.2 Brazil
-
5.3.1.3 Argentina
-
5.3.1.4 Rest of Latin America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 AstraZeneca Plc.
-
6.1.2 Bristol Myers Squibb
-
6.1.3 Celgene Corporation
-
6.1.4 Eli Lilly and Co.
-
6.1.5 GlaxoSmithKline Plc.
-
6.1.6 Merck & Co., Inc.
-
6.1.7 Johnson and Johnson
-
6.1.8 Novartis AG
-
6.1.9 Pfizer Inc.
-
6.1.10 Sanofi S.A.
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Latin America Bladder Cancer Therapeutics & Diagnostics Industry Segmentation
Bladder cancer is a urologic malignancy arising from the epithelial lining of the urinary bladder. Bladder cancer therapeutics are procedures that inhibit and stunt the growth or kill the cancer cells. Diagnostics techniques include methods that help in the diagnosis of bladder cancer.
In the report, a detailed analysis of the bladder cancer therapeutics and diagnostics market in Latin America is provided. The market is evaluated by collating revenues generated across segments, categorized by Cancer Type, by Therapeutics and Diagnostics, and Geography.
| By Cancer Type | |
| Transitional Cell Bladder Cancer | |
| Superficial Bladder Cancer | |
| Invasive Bladder Cancer | |
| Squamous Cell Bladder Cancer | |
| Other Rare Types |
| By Therapeutics and Diagnostics | |||||||
| |||||||
|
| Geography | ||||||
|
Latin America Bladder Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current Latin America Bladder Cancer Therapeutics & Diagnostics Market size?
The Latin America Bladder Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 3.40% during the forecast period (2024-2029)
Who are the key players in Latin America Bladder Cancer Therapeutics & Diagnostics Market?
Pfizer Inc, Johnson and Johnson, AstraZeneca Plc., Bristol Myers Squibb and Merck & Co Inc are the major companies operating in the Latin America Bladder Cancer Therapeutics & Diagnostics Market.
What years does this Latin America Bladder Cancer Therapeutics & Diagnostics Market cover?
The report covers the Latin America Bladder Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Latin America Bladder Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Latin America Bladder Cancer Therapeutics & Diagnostics Industry Report
Statistics for the 2024 Latin America Bladder Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America Bladder Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Latin America Bladder Cancer Therapeutics & Diagnostics Report Snapshots
